Status:
COMPLETED
The Role of IL-22/IL-22BP Axis in Atopic Dermatitis
Lead Sponsor:
Nantes University Hospital
Collaborating Sponsors:
Plateforme CIMNA, Laboratoire d'Immunologie, Nantes University Hospital
UCB Biopharma SRL
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Interleukin 22 (IL-22) is known to be regulated by IL-22 binding protein (IL-22BP), a soluble, inhibitory receptor. The potential role of IL-22BP in atopic dermatitis (AD) is mostly unknown and deserv...
Detailed Description
This is a single-visit study. All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area . It is planned to include 45 patients (15 patients per sever...
Eligibility Criteria
Inclusion
- Patients with AD according to UK Working Party criteria
- Patients affiliated to French social security system
- Patients who gave written consent after reading the protocol
- Moderate to severe AD (SCORAD score\>25)
- Presence of at least one lesional and one non-lesional skin area in the area covered by the clothing
- No immunosuppressive systemic treatment in progress for at least 3 months or biologics for at least 4 months
Exclusion
- Minor patients
- Pregnant and/or breastfeeding women
- Patients under guardianship or tutorship
- Inability to understand information and instructions
- Patients undergoing systemic immunosuppressive treatment for at least 3 months or biologics for at least 4 months
- Patient included in a clinical trial
- Documented allergy to the anesthetic (xylocain)
Key Trial Info
Start Date :
December 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 29 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04310189
Start Date
December 2 2020
End Date
November 29 2022
Last Update
December 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nantes University Hospital
Nantes, France